NAVB vs. MYMD, VRAX, BMRA, TRIB, MBIO, EVOK, SNES, UTRS, FNCH, and MDGS
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Biomerica (BMRA), Trinity Biotech (TRIB), Mustang Bio (MBIO), Evoke Pharma (EVOK), SenesTech (SNES), Minerva Surgical (UTRS), Finch Therapeutics Group (FNCH), and Xylo Technologies (MDGS). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
Navidea Biopharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.
0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 2.6% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Navidea Biopharmaceuticals' return on equity of 0.00% beat MyMD Pharmaceuticals' return on equity.
In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 2 mentions for Navidea Biopharmaceuticals and 1 mentions for MyMD Pharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score.
MyMD Pharmaceuticals has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Navidea Biopharmaceuticals and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users.
Summary
Navidea Biopharmaceuticals and MyMD Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
